Company Filing History:
Years Active: 2020-2025
Title: Greg Petsko: Innovator in ALS Research
Introduction
Greg Petsko is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of neuroscience, particularly in the study of amyotrophic lateral sclerosis (ALS). With a total of 3 patents, Petsko has made strides in understanding and potentially treating this devastating disease.
Latest Patents
His latest patents focus on methods of reducing FUS/TLS- or TDP-43-mediated neuronal cytotoxicity in ALS. One patent describes the use of UPF2 - Nonsense-mediated mRNA decay (NMD) polypeptides, along with nucleic acids encoding these polypeptides, and methods for utilizing them in the treatment of ALS. Another patent similarly addresses the role of UPF1 - Nonsense-mediated mRNA decay (NMD) polypeptides in reducing neuronal cytotoxicity associated with ALS.
Career Highlights
Greg Petsko is affiliated with Brandeis University, where he continues to advance research in ALS and related fields. His work has garnered attention for its potential to lead to new therapeutic strategies for patients suffering from this condition.
Collaborations
Some of his notable coworkers include Dagmar Ringe and Shulin Ju, who have collaborated with him on various research projects aimed at understanding the molecular mechanisms underlying ALS.
Conclusion
Greg Petsko's innovative research and patents represent a significant step forward in the fight against ALS. His contributions to the field are invaluable and hold promise for future advancements in treatment options.